Korean Drug Co., Ltd. (KOSDAQ:014570)
South Korea · Delayed Price · Currency is KRW 4,250.00
+20.00 (0.47%)
At close: Oct 28, 2025
Korean Drug Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 62,744 | 73,001 | 81,375 | 79,984 | 74,466 | 66,789 | Upgrade |
Other Revenue | - | - | -0 | -0 | -0 | - | Upgrade |
| 62,744 | 73,001 | 81,375 | 79,984 | 74,466 | 66,789 | Upgrade | |
Revenue Growth (YoY) | -19.48% | -10.29% | 1.74% | 7.41% | 11.49% | 20.28% | Upgrade |
Cost of Revenue | 34,971 | 38,600 | 44,025 | 45,467 | 43,400 | 38,100 | Upgrade |
Gross Profit | 27,774 | 34,401 | 37,350 | 34,517 | 31,065 | 28,689 | Upgrade |
Selling, General & Admin | 23,336 | 24,137 | 18,136 | 19,111 | 18,529 | 16,530 | Upgrade |
Amortization of Goodwill & Intangibles | 81.03 | 169.6 | 197.35 | 156.68 | 248.27 | 151.14 | Upgrade |
Other Operating Expenses | 546.96 | 677.64 | 724.2 | 662 | 745.93 | 662.9 | Upgrade |
Operating Expenses | 24,367 | 30,296 | 30,630 | 20,188 | 19,799 | 17,650 | Upgrade |
Operating Income | 3,407 | 4,105 | 6,720 | 14,329 | 11,266 | 11,039 | Upgrade |
Interest Expense | -3.98 | -4.24 | -3.02 | -2.1 | -1.53 | -3.13 | Upgrade |
Interest & Investment Income | 671.45 | 594.69 | 1,213 | 621.01 | 133.66 | 166.91 | Upgrade |
Earnings From Equity Investments | - | - | - | - | - | -576.86 | Upgrade |
Currency Exchange Gain (Loss) | 6.37 | 3.48 | 1.55 | 84.73 | 98.22 | -74.65 | Upgrade |
Other Non Operating Income (Expenses) | 210.41 | 218.47 | 205.88 | 32.88 | 182.37 | 227.81 | Upgrade |
EBT Excluding Unusual Items | 4,291 | 4,917 | 8,137 | 15,066 | 11,679 | 10,779 | Upgrade |
Gain (Loss) on Sale of Investments | 11.1 | 72.9 | 132.87 | -383.6 | -359.46 | -1,534 | Upgrade |
Gain (Loss) on Sale of Assets | 3.87 | 3.56 | -4.78 | 2.81 | 1.13 | -5.28 | Upgrade |
Pretax Income | 4,306 | 4,994 | 8,265 | 14,685 | 11,321 | 9,240 | Upgrade |
Income Tax Expense | 756.97 | 1,998 | 13,182 | 2,876 | 2,278 | 1,880 | Upgrade |
Net Income | 3,549 | 2,995 | -4,917 | 11,809 | 9,042 | 7,360 | Upgrade |
Net Income to Common | 3,549 | 2,995 | -4,917 | 11,809 | 9,042 | 7,360 | Upgrade |
Net Income Growth | - | - | - | 30.59% | 22.86% | 88.94% | Upgrade |
Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | 11 | Upgrade |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | 11 | Upgrade |
Shares Change (YoY) | 0.22% | 0.08% | -0.01% | -1.30% | 0.56% | -0.33% | Upgrade |
EPS (Basic) | 328.41 | 277.55 | -455.98 | 1095.09 | 827.64 | 677.40 | Upgrade |
EPS (Diluted) | 328.41 | 277.55 | -455.98 | 1095.09 | 827.64 | 677.40 | Upgrade |
EPS Growth | - | - | - | 32.31% | 22.18% | 89.57% | Upgrade |
Free Cash Flow | 8,932 | 3,842 | -2,119 | -180.15 | 7,660 | 11,592 | Upgrade |
Free Cash Flow Per Share | 826.44 | 356.01 | -196.53 | -16.71 | 701.12 | 1066.91 | Upgrade |
Gross Margin | 44.27% | 47.12% | 45.90% | 43.16% | 41.72% | 42.95% | Upgrade |
Operating Margin | 5.43% | 5.62% | 8.26% | 17.91% | 15.13% | 16.53% | Upgrade |
Profit Margin | 5.66% | 4.10% | -6.04% | 14.76% | 12.14% | 11.02% | Upgrade |
Free Cash Flow Margin | 14.24% | 5.26% | -2.60% | -0.22% | 10.29% | 17.36% | Upgrade |
EBITDA | 5,413 | 6,174 | 8,469 | 15,712 | 12,736 | 12,394 | Upgrade |
EBITDA Margin | 8.63% | 8.46% | 10.41% | 19.64% | 17.10% | 18.56% | Upgrade |
D&A For EBITDA | 2,006 | 2,069 | 1,749 | 1,383 | 1,470 | 1,355 | Upgrade |
EBIT | 3,407 | 4,105 | 6,720 | 14,329 | 11,266 | 11,039 | Upgrade |
EBIT Margin | 5.43% | 5.62% | 8.26% | 17.91% | 15.13% | 16.53% | Upgrade |
Effective Tax Rate | 17.58% | 40.02% | 159.49% | 19.58% | 20.13% | 20.35% | Upgrade |
Advertising Expenses | - | 900.89 | 920.23 | 1,014 | 1,082 | 1,231 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.